The {pharmaceutical market is currently exploring innovative treatment strategies for obesity , and the introduction of semaglutide 10mg injectables represents the change. Clinicians are now assess the possible benefits and challenges associated with this stronger concentration product, particularly in comparison to existing lower-dose semaglutide